Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 2, 1999, Pages 865-869

  Gutiérrez Puente, Yolanda ^a,b   Tari, Ana M ^a   Stephens, Clifton ^a   Rosenblum, Michael ^a   Guerra, Reyes Tamez ^a,b   Lopez Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RESEARCH; DRUG SAFETY; HEMATOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; GENES, BCL-2; KIDNEY; LIPOSOMES; LIVER; MICE; MICE, INBRED ICR; RATS; RATS, INBRED LEW; SPLEEN; TISSUE DISTRIBUTION;

EID: 0345426344     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Agrawal S (1996) Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol 14:376-387.
2. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin J, Yan J, Cai H, Diasio R, Habus I and Jiang Z (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50:571-576.
3. Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H and Heath J (1997) Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 7:575-584.
4. Alama AF, Barbieri M, Cagnoli M and Schettini G (1997) Antisense oligonucleotides as therapeutic agents. Pharmacol Res 36:171-178.
5. Altman P (1985) The Biology Databook. FASEB and Pergamon Inforline, Bethesda, MD.
6. Beham A, Marin M, Fernandez A, Hermann J, Brisbay S, Tari A, Lopez-Berestein G, Lozano G, Sarkiss M and McDonnell T (1997) Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15:2767-2772.
7. Cotter F (1997) Antisense therapy for lymphomas. Hematol Oncol 15:3-11.
8. de Smidt P, Doan T, de Falco S and van Berkel T (1991) Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acid Res 19:4695-4700.
9. DeLong R, Nolting A, Fisher M, Chen Q, Wickstrom E, Kligshteyn M, Demirdji S, Caruthers M and Juliano R (1997) Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev 7:71-77.
10. Leonetti C, D'Agano I, Lozupone F, Valentini A, Geiser T, Zon G, Citro G and Zupi G (1996) Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 88:419-429.
11. Litzinger D, Brown J, Wala I, Kaufman S, Van G, Farrell C and Collins D (1996) Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1281:139-149.
12. Lopez-Berestein G, Rosemblum M, Sadeghi T and Mehta K (1994) Pharmacokinaetics, tissue distribution, and toxicology of tretinoin incorporated in liposomes. J Liposome Res 4:689-700.
13. Miyashita TS, Kitada W, Horne DD and Reed JC (1995) Overexpression of the Bcl-2 protein increases the half-life of p21 Bax. J Biol Chem 270:26049-26052.
14. Neilan JZ, Luz C, Alfonso G, Kutish M, Sussman MD and Rock D (1993) An African swine fever virus with similarity to the protooncogene Bcl-2 and the Epstein-Barr virus gene BHRF1. J Virol 67:4391-4394.
15. Raynaud F, Orr R, Goddard P, Lacely H, Lancashire H, Judson I, Beck T, Brya B and Cotter F (1997) Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to Bcl-2, after intravenous administration or continues subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-427.
16. Reed JC (1995) Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am (1995) 9:451-473.
17. Tari A and Lopez-Berestein G (1997) Oligonucleotide therapy for hematological malignancies. J Liposome Res 7:19-30.
18. Tari A, Neamati N, Andreeff M and Lopez-Berestein G (1996) Liposomal delivery of P-ethoxy antisense oligodeoxynucleotides in chronic myelogenous leukemia, in Targeting of Drugs: Strategies for Oligonucleotide and Gene Delivery in Therapy (Gregoriadis G and McCormack B eds), pp 163-168, Plenum Press, New York.
19. Tari A, Stephens C, Rosenblum M and Lopez-Berestein G (1998) Pharmacokinetics, tissue distribution, and safety of P-ethoxy oligonucleotides incorporated in liposomes. J Liposome Res 8:251-264.
20. Temsamani J and Guinot P (1997) Antisense oligonucleotides: A new therapeutic approach. Biotechnol Appl Biochem 26:65-71.
21. Tormo M, Tari A, McDonell T, Cabanillas F, Garcia-Conde J and Lopez-Berestein G (1998) Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma 30:367-379.
22. Tsujimoto Y, Cossman J and Croce C (1985) Involvement of the Bcl-2 gene in human follicular lymphoma. Science (Wash DC) 228:1440-1443.
23. Zou Y, Preibe W, Ling Y and Perez-Soler R (1993) Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother Pharmacol 32:190-196.